Literature DB >> 21725672

Influence of radiofrequency ablation of lung cancer on pulmonary function.

Akihiro Tada1, Takao Hiraki, Toshihiro Iguchi, Hideo Gobara, Hidefumi Mimura, Shinichi Toyooka, Katsuyuki Kiura, Toshihide Tsuda, Toshiharu Mitsuhashi, Susumu Kanazawa.   

Abstract

PURPOSE: The purpose of this study was to evaluate altered pulmonary function retrospectively after RFA.
METHODS: This retrospective study comprised 41 ablation sessions for 39 patients (22 men and 17 women; mean age, 64.8 years). Vital capacity (VC) and forced expiratory volume in 1 s (FEV(1)) at 1 and 3 months after RFA were compared with the baseline (i.e., values before RFA). To evaluate the factors that influenced impaired pulmonary function, univariate analysis was performed by using multiple variables. If two or more variables were indicated as statistically significant by univariate analysis, these variables were subjected to multivariate analysis to identify independent factors.
RESULTS: The mean VC and FEV(1) before RFA and 1 and 3 months after RFA were 3.04 and 2.24 l, 2.79 and 2.11 l, and 2.85 and 2.13 l, respectively. The values at 1 and 3 months were significantly lower than the baseline. Severe pleuritis after RFA was identified as the independent factor influencing impaired VC at 1 month (P = 0.003). For impaired FEV(1) at 1 month, only severe pleuritis (P = 0.01) was statistically significant by univariate analysis. At 3 months, severe pleuritis (VC, P = 0.019; FEV(1), P = 0.003) and an ablated parenchymal volume ≥20 cm(3) (VC, P = 0.047; FEV(1), P = 0.038) were independent factors for impaired VC and FEV(1).
CONCLUSIONS: Pulmonary function decreased after RFA. RFA-induced severe pleuritis and ablation of a large volume of marginal parenchyma were associated with impaired pulmonary function.

Entities:  

Mesh:

Year:  2011        PMID: 21725672     DOI: 10.1007/s00270-011-0221-z

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  6 in total

Review 1.  Systemic Versus Local Therapies for Colorectal Cancer Pulmonary Metastasis: What to Choose and When?

Authors:  Tony Ibrahim; Lambros Tselikas; Charbel Yazbeck; Joseph Kattan
Journal:  J Gastrointest Cancer       Date:  2016-09

Review 2.  Lung cancer ablation: what is the evidence?

Authors:  Thierry de Baere; Geoffroy Farouil; Frederic Deschamps
Journal:  Semin Intervent Radiol       Date:  2013-06       Impact factor: 1.513

Review 3.  Radiofrequency ablation as treatment for pulmonary metastasis of colorectal cancer.

Authors:  Takao Hiraki; Hideo Gobara; Toshihiro Iguchi; Hiroyasu Fujiwara; Yusuke Matsui; Susumu Kanazawa
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

4.  Percutaneous radiofrequency ablation for patients with malignant lung tumors: a phase II prospective multicenter study (JIVROSG-0702).

Authors:  Hideo Gobara; Yasuaki Arai; Takeshi Kobayashi; Koichiro Yamakado; Yoshitaka Inaba; Yoshihisa Kodama; Takuji Yamagami; Miyuki Sone; Hirokazu Watanabe; Yoshihiro Okumura; Takayoshi Shinya; Hiroaki Kurihara; Susumu Kanazawa
Journal:  Jpn J Radiol       Date:  2016-06-03       Impact factor: 2.374

Review 5.  Current Management of Oligometastatic Lung Cancer and Future Perspectives: Results of Thermal Ablation as a Local Ablative Therapy.

Authors:  Mario Ghosn; Stephen B Solomon
Journal:  Cancers (Basel)       Date:  2021-10-16       Impact factor: 6.639

6.  Lung radiofrequency ablation: potential as a therapy to oligometastasis and oligorecurrence.

Authors:  Takao Hiraki; Susumu Kanazawa
Journal:  Pulm Med       Date:  2012-10-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.